Liver Transplantation in Hepatitis B/Hepatitis D (Delta) Virus Coinfected Recipients.
Journal
Transplantation
ISSN: 1534-6080
Titre abrégé: Transplantation
Pays: United States
ID NLM: 0132144
Informations de publication
Date de publication:
01 10 2022
01 10 2022
Historique:
pubmed:
12
4
2022
medline:
4
10
2022
entrez:
11
4
2022
Statut:
ppublish
Résumé
Hepatitis D is caused by the hepatitis D virus (HDV); it is the most severe form of viral hepatitis in humans, running an accelerated course to cirrhosis. There is no efficacious therapy, and liver transplantation provides the only therapeutic option for terminal HDV disease. However, HDV infection is prevalent in poor countries of the world with no access to liver transplant programs; liver grafting has been performed in high-income countries, where the prevalence of the infection has much diminished as a secondary effect of hepatitis B virus vaccination, and the demand for liver transplantation outlives in aging cirrhotics who acquired hepatitis D decades ago. This review describes the evolution of liver transplantation for HDV disease from its inception in 1987 to the present time, with an outlook to its future. It reports the progress in the prophylaxis of HDV reinfections to the success of the current standard of indefinite combination of hepatitis B virus antivirals with immunoglobulins against the hepatitis B surface antigen; however, the unique biology of the virus provides a rationale to reducing costs by limiting the administration of the immunoglobulins against the hepatitis B surface antigen.
Identifiants
pubmed: 35404869
doi: 10.1097/TP.0000000000004138
pii: 00007890-202210000-00011
doi:
Substances chimiques
Antiviral Agents
0
Hepatitis B Surface Antigens
0
Immunoglobulins
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1935-1939Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest. R.R. consults for Biotest Italia and for Kedrion Biopharma. The remaining authors declare no conflicts of interest.
Références
Rizzetto M. Hepatitis D virus. Wong RJ, Gish EG, eds. In: Clinical Epidemiology of Chronic Liver Disease. Springer. 2019:135–148.
Taylor JM. Infection by Hepatitis Delta virus. Viruses. 2020;12:E648.
Chen HY, Shen DT, Ji DZ, et al. Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis. Gut. 2019;68:512–521.
Stockdale AJ, Kreuels B, Henrion MYR, et al. The global prevalence of hepatitis D virus infection: systematic review and meta-analysis. J Hepatol. 2020;73:523–532.
Miao Z, Zhang S, Ou X, et al. Estimating the global prevalence, disease progression, and clinical outcome of hepatitis delta virus infection. J Infect Dis. 2020;221:1677–1687.
Rizzetto M, Hamid S, Negro F. The changing context of hepatitis D. J Hepatol. 2021;74:1200–1211.
Farci P, Niro GA. Clinical features of hepatitis D. Semin Liver Dis. 2012;32:228–236.
Fattovich G, Giustina G, Christensen E, et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep). Gut. 2000;46:420–426.
Yurdaydin C. Treatment of chronic delta hepatitis. Semin Liver Dis. 2012;32:237–244.
Wranke A, Pinheiro Borzacov LM, Parana R, et al.; Hepatitis Delta International Network. Clinical and virological heterogeneity of hepatitis delta in different regions world-wide: The Hepatitis Delta International Network (HDIN). Liver Int. 2018;38:842–850.
Kushner T, Da BL, Chan A, et al. Liver transplantation for hepatitis D virus in the United States: a UNOS Study on Outcomes in the MELD Era. Transplant Direct. 2022;8:e1253.
Popescu I, Ionescu M, Braşoveanu V, et al. The romanian national program for liver transplantation—852 procedures in 815 patients over 17 Years (2000-2017): a continuous evolution to success. Chirurgia (Bucur). 2017;112:229–243.
Moysyuk YG, Malinovskaya YO, Bel’skikh LV, et al. Liver transplantation in the Moscow Region: the regional project and its implementation. Almanac Clin Med. 2018;46:572–583.
Rizzetto M, Ciancio A. Epidemiology of hepatitis D. Semin Liver Dis. 2012;32:211–219.
Kushner T, Serper M, Kaplan DE. Delta hepatitis within the Veterans Affairs medical system in the United States: prevalence, risk factors, and outcomes. J Hepatol. 2015;63:586–592.
Safaie P, Razeghi S, Rouster SD, et al. Hepatitis D diagnostics: utilization and testing in the United States. Virus Res. 2018;250:114–117.
Rizzetto M, Macagno S, Chiaberge E, et al. Liver transplantation in hepatitis delta virus disease. Lancet. 1987;2:469–471.
Ottobrelli A, Marzano A, Smedile A, et al. Patterns of hepatitis delta virus reinfection and disease in liver transplantation. Gastroenterology. 1991;101:1649–1655.
Zignego AL, Samuel D, Gentilini P, et al. Patterns and mechanisms of hepatitis B/hepatitis D reinfection after liver transplantation. Arch Virol Suppl. 1993;8:281–289.
Lucey MR, Graham DM, Martin P, et al. Recurrence of hepatitis B and delta hepatitis after orthotopic liver transplantation. Gut. 1992;33:1390–1396.
Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med. 1993;329:1842–1847.
Samuel D, Zignego AL, Reynes M, et al. Long-term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis. Hepatology. 1995;21:333–339.
David E, Rahier J, Pucci A, et al. Recurrence of hepatitis D (delta) in liver transplants: histopathological aspects. Gastroenterology. 1993;104:1122–1128.
Roche B, Samuel D. Liver transplantation in delta virus infection. Semin Liver Dis. 2012;32:245–255.
Duvoux C, Belli LS, Fung J, et al. 2020 position statement and recommendations of the European Liver and Intestine Transplantation Association (ELITA): management of hepatitis B virus-related infection before and after liver transplantation. Aliment Pharmacol Ther. 2021;54:583–605.
European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370–398.
Buchanan C, Tran TT. Current status of liver transplantation for hepatitis B virus. Clin Liver Dis. 2011;15:753–764.
Williams V, Brichler S, Radjef N, et al. Hepatitis delta virus proteins repress hepatitis B virus enhancers and activate the alpha/beta interferon-inducible MxA gene. J Gen Virol. 2009;90:2759–2767.
Caccamo L, Agnelli F, Reggiani P, et al. Role of lamivudine in the posttransplant prophylaxis of chronic hepatitis B virus and hepatitis delta virus coinfection. Transplantation. 2007;83:1341–1344.
Tandoi F, Caviglia GP, Olivero A, et al. Liver transplantation for hepatitis B with delta coinfection: a single Center experience. J Viral Hepat. 2015;22:110–111.
Beckebaum S, Herzer K, Bauhofer A, et al. Recurrence of hepatitis B infection in liver transplant patients receiving long-term hepatitis B immunoglobulin prophylaxis. Ann Transplant. 2018;23:789–801.
Adil B, Fatih O, Volkan I, et al. Hepatitis B virus and hepatitis D virus recurrence in patients undergoing liver transplantation for hepatitis B virus and hepatitis B virus plus hepatitis D virus. Transplant Proc. 2016;48:2119–2123.
Serin A, Tokat Y. Recurrence of hepatitis D virus in liver transplant recipients with hepatitis B and D virus-related chronic liver disease. Transplant Proc. 2019;51:2457–2460.
Al-hamoudi W, Ali S, Elsiesy H, et al. Long term transplant outcome of hepatitis B virus and hepatitis delta virus coinfection. Am J Transplant. 2013;13(Suppl 5):B1076.
Lima DS, Murad Júnior AJ, Barreira MA, et al. Liver transplantation in hepatitis delta: south america experience. Arq Gastroenterol. 2018;55:14–17.
Saparbay J, Spatayev J, Sharmenov A, et al. Liver transplantation: a 10-year low-volume transplant center experience in Kazakhstan. Ann Transplant. 2021;26:e931786.
Cholongitas E, Goulis I, Antoniadis N, et al. New nucleos(t)ide analogue monoprophylaxis after cessation of hepatitis B immunoglobulin is effective against hepatitis B recurrence. Transpl Int. 2014;27:1022–1028.
Radhakrishnan K, Chi A, Quan DJ, et al. Short course of postoperative hepatitis B immunoglobulin plus antivirals prevents reinfection of liver transplant recipients. Transplantation. 2017;101:2079–2082.
Manini MA, Whitehouse G, Bruce M, et al. Entecavir or tenofovir monotherapy prevents HBV recurrence in liver transplant recipients: A 5-year follow-up study after hepatitis B immunoglobulin withdrawal. Dig Liver Dis. 2018;50:944–953.
Dobrindt EM, Keshi E, Salim Y, et al. Hepatitis B Immunoglobulin discontinuation in long-term liver transplant patients. Transpl Infect Dis. 2020;22:e13303.
Muhammad H, Tehreem A, Hammami MB, et al. Hepatitis D virus and liver transplantation: indications and outcomes. World J Hepatol. 2021;13:291–299.
Fung J, Wong T, Chok K, et al. Long-term outcomes of entecavir monotherapy for chronic hepatitis B after liver transplantation: results up to 8 years. Hepatology. 2017;66:1036–1044.
Wadhawan M, Gupta S, Goyal N, et al. Living related liver transplantation for hepatitis B-related liver disease without hepatitis B immune globulin prophylaxis. Liver Transpl. 2013;19:1030–1035.
Mederacke I, Filmann N, Yurdaydin C, et al. Rapid early HDV RNA decline in the peripheral blood but prolonged intrahepatic hepatitis delta antigen persistence after liver transplantation. J Hepatol. 2012;56:115–122.
Tseng CH, Lai MM. Hepatitis delta virus RNA replication. Viruses. 2009;1:818–831.
Smedile A, Casey JL, Cote PJ, et al. Hepatitis D viremia following orthotopic liver transplantation involves a typical HDV virion with a hepatitis B surface antigen envelope. Hepatology. 1998;27:1723–1729.
Ossami Saidy RR, Sud I, Eurich F, et al. Discontinuation of passive immunization is safe after liver transplantation for combined HBV/HDV infection. Viruses. 2021;13:904.
Caccamo L. Long-term nucleos(t)ide analog(s) monoprophylaxis in Delta coinfected liver transplant recipients. Transpl Infect Dis. 2017;19.
Cholongitas E, Goulis I, Antoniadis N, et al. Nucleos(t)ide analog(s) prophylaxis after hepatitis B immunoglobulin withdrawal against hepatitis B and D recurrence after liver transplantation. Transpl Infect Dis. 2016;18:667–673.
Fernández I, Loinaz C, Hernández O, et al. Tenofovir/entecavir monotherapy after hepatitis B immunoglobulin withdrawal is safe and effective in the prevention of hepatitis B in liver transplant recipients. Transpl Infect Dis. 2015;17:695–701.
Öcal S, Korkmaz M, Harmanci Ö, et al. Hepatitis B- and hepatitis D-virus-related liver transplant: single-center data. Exp Clin Transplant. 2015;13(Suppl 1):133–138.
Martini S, Caccamo L, Rizzetto M. Are immunoglobulins against the HBsAg still needed in liver transplantation for hepatitis D? Hepatology. 2018;67:2475–2476.
Adam R, Karam V, Cailliez V, et al.; all the other 126 contributing centers ( www.eltr.org ) and the European Liver and Intestine Transplant Association (ELITA). 2018 Annual Report of the European Liver Transplant Registry (ELTR)—50-year evolution of liver transplantation. Transpl Int. 2018;31:1293–1317.
Caviglia GP, Martini S, Ciancio A, et al. The hepatitis D virus in Italy. A vanishing infection, not yet a vanished disease. J Adv Res. 2021;33:183–187.
Stroffolini T, Ciancio A, Furlan C, et al. Migratory flow and hepatitis delta infection in Italy: a new challenge at the beginning of the third millennium. J Viral Hepat. 2020;27:941–947.
Loureiro D, Castelnau C, Tout I, et al. New therapies for hepatitis delta virus infection. Liver Int. 2021;41(Suppl 1):30–37.
European Medicines Agency. Hepcludex. Available at https://www.ema.europa.eu/en/medicines/human/EPAR/hepcludex . Accessed on February 12, 2022.